The company will present at the JP Morgan Healthcare conference
CHARLOTTE, NC, Jan. 14, 2025 (GLOBE NEWSWIRE) — DENTSPLY SIRONA (NASDAQ: ) Inc . (Dentsply Sirona or the “Company”) (Nasdaq: XRAY) announced today that the company plans to refocus Byte’s business model around treatments that include extended personal supervision by dentists. The company is evaluating a business and economic go-to-market model and expects to leverage direct-to-consumer (DTC) collaborative demand generation with dentists leveraging Byte’s core competencies, expand customer digital journey management across a portfolio of adjusters, and leverage Byte’s skill sets to further enhance customer service and marketing throughout the company. As of this review, Dentsply Sirona is not recalling home byte alignment systems and impression kits, but will continue to support patients who do not have contraindications to byte alignment currently undergoing treatment. Dentsply Sirona will continue to cooperate with regulatory authorities and obtain all necessary approvals prior to any market launch.
Our actions demonstrate our continued commitment to quality and compliance in everything we do. With this in mind and in line with Dentsply Sirona’s goal of enabling access to quality care for a broad patient population, we plan to redefine Byte’s business model while leveraging their strong capabilities including the DTC engine, said Simon Campion, President and CEO of Dentsply Sirona. We believe there is applicability to creating DTC claims in dentistry, including aligners, and have already begun implementing Byte’s strategic capabilities across our company.
JP Morgan Healthcare Conference
As previously announced, Dentsply Sirona will be presented at the 43rdrd JP Morgan Healthcare Annual Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT (10:30 a.m. ET). During the presentation, representatives of the Company will present materials attached to the Company’s Form 8-K filed today with the Securities and Exchange Commission (SEC). The company also expects to discuss Byte’s announcement as part of that presentation.
Presentation materials and webcast information for the investor conference, including a replay of the post-conference webcast, will be available in the investor section of Dentsply Sirona’s website at https://investor.dentsplysirona.com.
About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with more than a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures and markets a comprehensive range of solutions including dental and oral health products as well as other consumable medical devices across a strong portfolio of world-class brands. Dentsply Sirona products provide innovative, high-quality and effective solutions to improve patient care and provide better and safer dental care. Dentsply Sirone is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact information:
Investors:
Andrea Daley
Vice President, Investor Relations
+1-704-591-8631
InvestorRelations@dentsplysirona.com
Forward-looking statements and related risks
This press release contains statements that do not relate directly and solely to historical facts that constitute forward-looking statements, including statements and projections regarding the ability to successfully realign Byte’s business or the ability to leverage Byte’s assets to support other aspects of the Company’s business . . The Company’s forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ materially from those anticipated or suggested in any forward-looking statements, and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date on which they are made. Forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are beyond our control. The Company undertakes no obligation to publicly announce any changes to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company’s actual results to differ materially from those anticipated by any forward-looking statements, including but not limited to risks associated with the following: the Company’s ability to remain profitable in a highly competitive market, which depends on the ability Company to differentiate its products and services from those of competitors; failure of the Company to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company’s distribution channels for its products and the failure of the Company’s significant distributors to effectively manage their inventories; increased regulation affecting the Company’s operations including Byte; the Company’s failure to receive any regulatory approval necessary to commercialize any particular product or service offering; the Company’s ability to control costs and failure to realize the expected benefits of cost reduction and restructuring efforts and the Company’s failure to anticipate and adequately adapt to changes or trends within the rapidly changing dental industry. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (Risk Factors) of the Company’s most recent Annual Report on Form 10-K, including any amendments and any updated information that may be contained in the Company’s other filings with the SEC, when reviewing any forward-looking statement. The Company notes these factors to investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand that it is impossible to predict or identify all such factors or risks. As such, you should not consider either the foregoing lists, or the risks identified in the Company’s filings with the SEC, to be a complete discussion of all potential risks or uncertainties.
